Workforce Development
Supports talent pipeline development through education partnerships and workforce readiness programming initiatives
Cancer research and treatment center combining scientific discovery with comprehensive patient care
About Organization
Fred Hutchinson Cancer Center unites innovative research and compassionate care to prevent, treat, and eliminate cancer and infectious diseases worldwide. Based in Seattle, WA, the organization operates with $1.28 billion in annual revenue and employs 2,549 staff members coordinating 250 volunteers.
Workforce Development
Supports talent pipeline development through education partnerships and workforce readiness programming initiatives
Economic Growth
Promotes regional economic development through strategic partnerships and support for business expansion initiatives
Business Advocacy
Represents member interests in policy development and advocates for pro-business initiatives at local and state levels
Form 990 data showing organizational financial health and growth.
Revenue (2021)
$1.3B
+36.4% vs 2020
Expenses (2021)
$1.1B
+34.8% vs 2020
Assets (2021)
$3.0B
+95.4% vs 2020
Employees (2021)
2,549
+16.4% vs 2020
| Year | Revenue | Expenses | Assets | Employees |
|---|---|---|---|---|
| 2021 | $1,283,961,922 | $1,134,529,429 | $2,999,831,201 | 2,549 |
| 2020 | $940,996,725 | $841,344,866 | $1,535,470,671 | 2,189 |
| 2019 | $820,892,125 | $735,653,659 | $1,020,161,042 | 2,069 |
| 2018 | $757,282,570 | $684,323,509 | $753,310,466 | 1,917 |
| 2017 | $653,487,789 | $610,353,946 | $647,980,104 | 1,811 |
Source: IRS Form 990 filings. All figures in USD.
Identifies priority issues through stakeholder consultation and analysis of business community needs
Develops targeted initiatives based on member input and regional economic development priorities
Executes programs through partnerships with member organizations and community stakeholders
Evaluates outcomes through member feedback and tracks progress toward organizational objectives
Services and programs offered by Fred Hutchinson Cancer Center
Facilitates collaboration and development in cancer research through targeted programming and partnerships
Supports stakeholders through cancer research programming designed to address community needs
Facilitates collaboration and development in raise awareness and support research and treatment of childhood cancer. through targeted programming and partnerships
Provides structured support and resources for medical / public services initiatives across member organizations
Provides structured support and resources for young investigator award initiatives across member organizations
Meet the people behind Fred Hutchinson Cancer Center.
Stephen Graham practiced corporate and securities law for several decades as a partner at the major law firms of Perkins Coie LLP, Orrick LLP and Fenwick & West LLP until his retirement from the practice in 2022. Currently, he is chair of the board of directors of Washington Federal Bank, the largest bank headquartered in Washington state with more than $30 billion in assets. He also serves on the national board of Friends of the Children, where he served as chair until the end of 2025. He also serves on the Board of Directors of The Who We Are Project, an organization dedicated to learning about and maintaining awareness of anti-Black racism. In 2019, Graham was appointed to the Securities and Exchange Commission’s Advisory Committee on Small Business Capital Formation and co-chaired the Securities and Exchange Commission’s Advisory Committee on Small and Emerging Companies from 2011 to 2017. He received his JD from Yale Law School.
Dr. Thomas J. Lynch Jr. is a world-renowned scientist, highly respected oncologist and successful leader of National Cancer Institute-Designated Comprehensive Cancer Centers. As president and director of Fred Hutch and holder of the Raisbeck Endowed Chair, Lynch sets the strategic direction of the center, oversees centerwide initiatives and represents the Hutch’s interests to major partners and governmental bodies. He directs the Fred Hutch/University of Washington/Seattle Children's Cancer Consortium and is principal investigator of its Cancer Center Support Grant. Before becoming Fred Hutch’s sixth president in February 2020, Lynch was most recently chief scientific officer of Bristol Myers Squibb. Previously, he held leadership roles as CEO of Massachusetts General Physicians Organization, director of Yale Cancer Center, physician-in-chief at Yale’s Smilow Cancer Hospital, chief of hematology-oncology at Massachusetts General Hospital and professor of medicine at Harvard Medical Sch
Dr. Nancy Davidson is executive vice president and chief academic officer at Fred Hutch, overseeing all faculty affairs and education. She holds the Raisbeck Endowed Chair for Collaborative Research. Davidson, a breast cancer oncologist, has built a worldwide reputation for her expertise and leadership in this field, for her research teasing out the role of hormones in breast cancer growth, and for her impact on the development of new standards of care. She is past president of the American Society of Clinical Oncology and the American Association of Cancer Research. She has been elected to the National Academy of Medicine and the American Academy of Arts and Sciences.
A world-renowned scientist, highly respected oncologist and successful cancer center leader, Dr. Lynch is motivated by the patients he’s treated to break down silos and free the scientific creativity that will spark new cures. Dr. Lynch holds the Raisbeck Endowed Chair for the Fred Hutch president and director.
Dr. Robinson is responsible for operations at Fred Hutch including organizational strategy, operational excellence, and the safety and wellbeing of our employees and community. She oversees operational teams that support and accelerate science. These teams include Clinical Operations, Clinical Research Support, Compliance, Data Office, Enterprise Risk, Facilities & Campus Operations, Human Resources, Information Technology, and Research Administration & Clinical Labs. As part of the Fred Hutch Director’s Office, Dr. Robinson also leads Fred Hutch’s strategic planning efforts, working with departments and scientific divisions throughout the organization to ensure that Fred Hutch is positioned to achieve its mission and goals.
Nida Shekhani manages the strategy arm of operations at Fred Hutch. This area facilitates the organization’s strategic planning process to identify and establish strategic priorities and goals in order to achieve our mission and uphold our values. In her role, Shekhani oversees the strategic administrative departments and functions of Business Development, Government & Community Relations, Marketing and Communications, and Strategy.
Dr. Prescott, vice president and chief of staff for the Fred Hutch Director’s Office, facilitates information flow and decision-making through collaboration with both administrative and scientific partners throughout Fred Hutch. She also participates in the development of strategies and processes to advance key initiatives.
Ric Anderson is the cofounder and chief operating officer of Washington Holdings, a real estate company that acquires, develops, manages and invests in assets throughout the western U.S. The company is focused on northwest apartment buildings, west coast hospitality assets, and Silicon Valley research and development business parks. Anderson is a former partner at Lowe Enterprises, a Los Angeles-based real estate investment firm. He received his bachelor’s degree in mechanical engineering from the University of Washington and his master’s degree in business administration from the Anderson School of Management at the University of California, Los Angeles. He has been a long-time board member of Fred Hutch and currently holds board positions at the UW Medicine advisory board, Pacific Real Estate Institute and University Preparatory Academy.
Pete Shimer is the executive committee chair of the Cancer AI Alliance (CAIA), a startup venture among Fred Hutch, other cancer centers and leading technology companies that is developing a platform for improved cancer outcomes, using federated machine learning. Shimer has more than 40 years of executive management experience as well as ownership of enterprise-wide transformation, corporate development, and long-term strategic planning efforts at Deloitte. At Deloitte, he served as the interim Deloitte U.S. chief executive officer, chief operating officer twice, chief financial officer, chair of the U.S. Operating Committee, member and chair of the U.S. Executive Committee, and Seattle managing partner. He led client service relationships for several Fortune 500 companies in the consumer and service industries. Shimer received a BA in Accounting from the University of Washington. He is a member of the Board of Alaska Air Group, a board member for the University of Washington Foster Sch
Julie Nordstrom is a community leader and advocate for health and child development, with extensive experience in board governance and philanthropy. She serves on the Stanford University Department of Health Policy Advisory Board, advising on strategic initiatives to advance health policy innovation and research. She is also a member of the board of the Institute for Health Metrics and Evaluation at the University of Washington and chairs the Head Start Governance Board of Save the Children, which works in six states to provide early childhood development and learning. Previously, Nordstrom was a U.S. trustee of Save the Children, chair of the UW Medicine board and the UW Medical Center board, and founding co-chair of the UW Department of Global Health leadership council. A former practicing attorney at Stafford, Frey, Cooper and Stewart, she earned a law degree from Seattle University School of Law and a bachelor’s degree in political science from the University of Washington. She is
Jim Lico retired in June of 2025 from his role as founding president and CEO of Fortive, an industrial technology conglomerate based in Everett, Washington. Lico held his role at Fortive and membership on Fortive's board of directors since the company's founding in 2016. He previously served as the executive vice president and in other leadership positions at life sciences conglomerate Danaher for 20 years. Prior to Danaher, Lico held leadership positions at AlliedSignal and General Motors. He is also a member of the board of directors of Dupont. Jim received a Master’s in Management degree from Northwestern Kellogg School of Management and a Bachelor of Science degree in operations management from the University of Michigan Dearborn.
Sean Boyle is chief operating officer of Omniva, an AI infrastructure startup. Previously, Boyle served as chief operating officer of Wildlife Studios, a global mobile gaming company; chief financial officer of Amazon Web Services; and chief financial officer of Apptio, a software company based in Bellevue, Washington, that develops technology business-management applications. He also held various financial leadership positions at Ford Motor Company. Boyle earned a bachelor’s degree in commerce and a Master of Business Administration from the University of Windsor. He previously served as treasurer on the board of Rainier Prep, a charter school dedicated to improving educational outcomes for low-income students of color and immigrant students, and as a member of the board of directors for Splunk, where he chaired the audit committee.
Dr. Timothy Dellit is chief executive officer of UW Medicine, executive vice president for medical affairs, and Paul G. Ramsey Endowed Dean of the School of Medicine at the University of Washington. UW Medicine is an integrated clinical, research and learning health system with a single mission: to improve the health of the public. Its clinically integrated components include the UW School of Medicine; two hospitals, UW Medical Center and Harborview Medical Center; a network of primary care clinics, UW Medicine Primary Care; a large physician practice plan, UW Physicians; and Airlift Northwest, a fixed-wing and helicopter air ambulance service. Previously, Dellit served as chief medical officer for UW Medicine; executive vice dean for clinical affairs and vice president for medical affairs at the University of Washington; and president of UW Physicians. In his leadership roles, Dellit strives to advance UW Medicine's mission to improve the health of the public through providing high-qu
Leigh Morgan is chief executive officer of Imaginal Leadership Strategies, a global advisory firm that works with clients in health care, technology, academia and philanthropy. She previously served as chief strategy and operating officer at Nia Tero; chief operating officer of the Bill & Melinda Gates Foundation; associate chancellor at the UCSF; and vice president and global head of human resources at Genentech. Morgan is the immediate past chair of the Fred Hutch board and serves on the UW Medicine advisory board. She has served as an independent director at Curemark and Kymera Therapeutics and is a member of the Council on Foreign Relations. She also hosts The Space In Between podcast. Morgan earned a master’s degree in organization development from American University, a bachelor’s degree in religion from Duke University and an honorary Doctor of Humane Letters from the Asian University for Women.
Cheryl M. Scott provides executive and board level counsel on matters of strategy, leadership and governance as the major principal for McClintock Scott. From 1997-2004, she served as the president and CEO of the Seattle-based Group Health Cooperative. Scott’s 8-year tenure as CEO capped a distinguished 25-year career with the organization. Her time at Group Health was followed by 10 years with the Gates Foundation, first as their chief operating officer then followed by several years as their senior advisor in Global Health.
Michelle Seitz, is the founder and CEO of MeydenVest Partners, LLC., a private investment and strategic advisory firm. Prior to founding MeydenVest Partners, she served as chair and CEO of Russell Investments. Before joining Russell, Seitz was CEO of William Blair Investment Management and served on William Blair’s corporate board of directors. With over three decades as both a CEO and investor, Seitz brings deep experience in the financial sector. At the companies she has led, a hallmark of her approach was leveraging her platform and voice to improve peoples’ financial security.
Brad Simmons is president of UW Medicine Hospitals & Clinics and senior vice president for medical affairs at the University of Washington. Before joining UW Medicine, he worked at UC Davis, first as chief operating officer and later as chief administrator of UC Davis Medical Center and chief operating officer for the hospital division. Simmons previously served as chief operating officer at Saint Luke’s Hospital in Kansas City and senior vice president of medicine, surgical and emergency/trauma services at Parkland Health and Hospital System in Dallas. He earned a master’s degree in health care administration from Washington University School of Medicine and a bachelor’s degree in business administration from Baylor University.
Kathy Surace-Smith has over 35 years of experience advising or working in high-growth private and public companies in both the United States and Europe, including over 20 years of experience in the life sciences industry. From 2013 to 2024, she served as senior vice president and general counsel of NanoString Technologies in Seattle, a provider of spatial biology solutions to the scientific research community, where she managed the company’s legal, human resources and regulatory functions. Previously, she served as vice president and general counsel of SonoSite Inc., an ultrasound technology company based in Bothell, Washington.
Jeff Yurcisin is the CEO of Grove Collaborative, a leading destination for clean, sustainable, non-toxic products. His previous leadership includes leading multiple billion-dollar companies and served as a senior executive for 14 years at Amazon. Previously, Yurcisin served as president and CEO of Zulily, an ecommerce company that strives to deliver the best shopping experience for moms nationwide. He also served as CEO of Shopbop, a leading global fashion boutique. While at Amazon, he led the Apparel business and led Amazon’s Private Brands business. He is also on the Board of Governors of the Center for Creative Leadership. Yurcisin earned his bachelor’s degree in economics from Princeton University and graduated with honors from Harvard Business School.
1998
1998
Established to serve business community development and economic growth initiatives
2012
2012
Extended programming and membership services to serve broader regional business community
2021
2021
Achieved significant revenue growth reflecting expanded member services and regional programming
2026
2026
Maintains active programming serving member organizations and regional economic development priorities
Board members, advisors, and key contributors
Information compiled from IRS Form 990 and organizational materials.
Top compensated officers & key employees from IRS Form 990
Total Reported (2021)
$7.8M
Highest Paid
$982K
Aaron Crane
Compensated Officers
15
| Name | Title | Base | Other | Total | Hrs/Wk |
|---|---|---|---|---|---|
| Aaron Crane | Executive Vice President | $790,366 | $191,393 | $981,759 | 55 |
| Nancy Davidson MD | EVP Clinical Affairs, DIR Eff 4/22 | $861,197 | $43,744 | $904,941 | 37.4 |
| Theresa Mcdonnell | SVP, Chief Nursing Officer | $615,786 | $184,120 | $799,906 | 55 |
| Steven Huebner | VP, Chief Financial Officer | $652,598 | — | $652,598 | 55 |
| Tom Purcell MD | Chief Medical Officer | $608,783 | $5,538 | $614,321 | 55 |
| Kelly Patrick | VP, Chief Information Officer | $497,929 | $80,713 | $578,642 | 55 |
| Stephanie Mays | VP, Chief Legal Officer | $436,413 | $98,451 | $534,864 | 55 |
| Tami Deeb | VP, Chief Strategy Officer | $399,220 | $77,557 | $476,777 | 55 |
| Moreen Dudley | VP, Chief People Officer | $317,320 | $54,494 | $371,814 | 55 |
| Gretchen Hanna | DIR. Corporate Finance | $296,607 | $54,932 | $351,539 | 55 |
| Richard Lafrance | DIR. Pharmacy | $257,844 | $65,184 | $323,028 | 55 |
| Chad Hoggard | Chief Info Security Officer | $250,640 | $58,639 | $309,279 | 55 |
| Anna Andrews | Interim Proton Ctr Trans Lead | $306,278 | — | $306,278 | 55 |
| Nicki Nguyen-Colvin | DIR. Strategy & Bus DEV | $242,214 | $56,065 | $298,279 | 55 |
| Timothy Ehling | DIR. Nursing & Clin. OPS Integ. | $239,583 | $58,408 | $297,991 | 55 |
| Name | Title | Base | Other | Total | Hrs/Wk |
|---|---|---|---|---|---|
| Deborah Gentzen | VP, Chief Strategy Ofc (Thru 5/20) | $1,016,486 | $30,983 | $1,047,469 | 55 |
| Aaron Crane | Executive Vice President | $721,479 | $174,523 | $896,002 | 55 |
| Nancy Davidson MD | Executive Director And President | $771,644 | $31,470 | $803,114 | 37.4 |
| Theresa Mcdonnell | SVP, Chief Nursing Officer | $447,693 | $159,460 | $607,153 | 55 |
| Barbara Jagels | VP, Chief Quality & Value Ofc | $406,239 | $154,815 | $561,054 | 55 |
| Stephanie Mays | VP, Chief Legal Officer | $415,592 | $95,567 | $511,159 | 55 |
| Steven Huebner | Chief Financial Officer | $491,745 | — | $491,745 | 55 |
| Tami Deeb | VP, Chief Strategy Officer | $305,875 | $58,113 | $363,988 | 55 |
| Moreen Dudley | VP, Chief People Officer | $286,272 | $45,622 | $331,894 | 55 |
| Gretchen Hanna | DIR. Corporate Finance | $286,550 | $45,140 | $331,690 | 55 |
| Richard Lafrance | DIR. Pharmacy | $245,789 | $64,636 | $310,425 | 55 |
| Kelly Patrick | VP, Chief Information Officer | $295,552 | $14,463 | $310,015 | 55 |
| Steven Johnson | DIR. Research Integr. (Thru 10/20) | $260,837 | $40,828 | $301,665 | 55 |
| Ada Mohedano | DIR. Clin. Analytics & Bus Intel | $261,301 | $39,319 | $300,620 | 55 |
| Traci Pranzini | Corporate Integrity Officer | $258,547 | $39,605 | $298,152 | 55 |
| Name | Title | Base | Other | Total | Hrs/Wk |
|---|---|---|---|---|---|
| Nancy Davidson MD | Executive Director And President | $810,563 | $32,227 | $842,790 | 37 |
| Norman Hubbard | Executive VP (Thru 4/19) | $725,046 | $33,631 | $758,677 | 55 |
| Aaron Crane | Executive Vice President | $586,077 | $137,313 | $723,390 | 55 |
| Deborah Gentzen | VP, Chief Strategy Offc (Thru 5/20) | $531,479 | $163,569 | $695,048 | 55 |
| Theresa Mcdonnell | Chief Nurse EXEC, VP-Clin OPS | $456,248 | $151,903 | $608,151 | 55 |
| Barbara Jagels | VP, Chief Quality & Value Offc | $451,520 | $153,158 | $604,678 | 55 |
| Stephanie Mays | VP, General Counsel | $391,417 | $73,709 | $465,126 | 55 |
| David Ackerson | VP, CIO (Thru 7/19) | $394,176 | $44,547 | $438,723 | 55 |
| F Marc Stewart MD | VP, Medical Director | $293,665 | $33,512 | $327,177 | 30 |
| Gretchen Hanna | DIR. Corporate Finance | $274,862 | $44,029 | $318,891 | 55 |
| Moreen Dudley | DIR. Clinic Operations | $268,266 | $43,759 | $312,025 | 55 |
| Tami Deeb | VP, Chief Strategy Officer | $259,808 | $48,153 | $307,961 | 55 |
| Richard Lafrance | DIR. Pharmacy | $236,018 | $63,423 | $299,441 | 55 |
| Alphonso Emery | DIR. Revenue Cycle Mgt. (Thru 8/19) | $263,548 | $22,954 | $286,502 | 55 |
| Traci Pranzini | Corporate Integrity Officer | $245,181 | $37,923 | $283,104 | 55 |
| Name | Title | Base | Other | Total | Hrs/Wk |
|---|---|---|---|---|---|
| Norman Hubbard | Executive VP (Thru 4/19) | $932,837 | $231,024 | $1,163,861 | 55 |
| Nancy Davidson MD | Executive Director And President | $929,406 | — | $929,406 | 45 |
| Deborah Gentzen | VP, Chief Strategy Officer | $505,671 | $152,782 | $658,453 | 55 |
| David Ackerson | VP, Chief Information Officer | $449,578 | $132,922 | $582,500 | 55 |
| F Marc Stewart MD | VP, Medical Director | $556,519 | — | $556,519 | 30 |
| Barbara Jagels | VP, Chief Quality & Value Offc | $405,660 | $140,585 | $546,245 | 55 |
| Theresa Mcdonnell | Chief Nurse EXEC, VP-Clin OPS | $405,596 | $135,994 | $541,590 | 55 |
| Stephanie Mays | General Counsel | $375,051 | $59,807 | $434,858 | 55 |
| Aaron Crane | Interim EXEC VP (From 4/19) & CFO | $279,676 | $37,655 | $317,331 | 55 |
| Gretchen Hanna | DIR. Corporate Finance | $272,735 | $38,329 | $311,064 | 55 |
| Tami Deeb | DIR. Service Lines | $255,762 | $42,026 | $297,788 | 55 |
| Joseph Norton | DIR. Finance | $254,996 | $41,674 | $296,670 | 55 |
| Moreen Dudley | DIR. Clin. OPS, Supportive SVCS | $246,007 | $34,803 | $280,810 | 55 |
| Kristine Logan | DIR. Operations | $236,101 | $32,436 | $268,537 | 55 |
| Nicki Nguyen-Colvin | DIR. Strategy & Bus DEV | $226,082 | $39,791 | $265,873 | 55 |
| Name | Title | Base | Other | Total | Hrs/Wk |
|---|---|---|---|---|---|
| Nancy Davidson MD | Executive Director And President | $1,273,027 | — | $1,273,027 | 45 |
| Norman Hubbard | Executive VP | $948,024 | $165,779 | $1,113,803 | 55 |
| Jonathan Tingstad | VP & CFO (Thru 10/17) | $634,441 | $55,362 | $689,803 | 55 |
| Deborah Gentzen | VP, Chief Strategy Officer | $423,869 | $111,983 | $535,852 | 55 |
| F Marc Stewart MD | VP, Medical Director | $515,591 | — | $515,591 | 55 |
| David Ackerson | VP, Chief Information Officer | $389,833 | $94,009 | $483,842 | 55 |
| Barbara Jagels | VP, Chief Quality & Value Offc | $353,516 | $101,199 | $454,715 | 55 |
| Theresa Mcdonnell | Chief Nurse EXEC, VP-Clin OPS | $348,640 | $50,425 | $399,065 | 55 |
| Gretchen Hanna | DIR. Corporate Finance | $255,771 | $35,490 | $291,261 | 55 |
| Joseph Norton | DIR. Finance | $239,040 | $38,582 | $277,622 | 55 |
| Maria Gonzalez | DIR. Research Int. (Thru 1/18) | $234,607 | $39,314 | $273,921 | 55 |
| Kristine Logan | DIR. Operations | $209,309 | $28,447 | $237,756 | 55 |
| Moreen Dudley | DIR. Clin. OPS, Supportive SVCS | $204,837 | $30,195 | $235,032 | 55 |
| Alphonso Emery | DIR. Revenue Cycle Mgt | $204,542 | $28,045 | $232,587 | 55 |
| Tami Deeb | DIR. Service Lines | $201,208 | $27,304 | $228,512 | 55 |
Source: IRS Form 990 filings. Compensation includes base and other reported compensation.
People from this organization who contributed to political campaigns
Spokane, WA
Rancho Mirage, CA
Seattle, WA
Bremerton, WA
Seattle, WA
Seattle, WA
Seattle, WA
Gwynn Oak, MD
Seattle, WA
Seattle, WA
Seattle, WA
Seattle, WA
Seattle, WA
Data from Federal Election Commission • Individual contributions only
Grant funding relationships from IRS Form 990 filings
Source: IRS Form 990 Schedule I filings. Amounts may span multiple tax years.
Government awards and grants from USAspending.gov
| Agency | Award ID | Type | Period | Amount |
|---|---|---|---|---|
| HHS | U24CA086368 | COOPERATIVE AGREEMENT (B) | 2000-2027 | $67,679,289 |
| HHS | P50CA097186 | PROJECT GRANT (B) | 2002-2028 | $38,742,250 |
| HHS | UM1AI069481 | COOPERATIVE AGREEMENT (B) | 2007-2027 | $23,611,215 |
| HHS | P50CA228944 | PROJECT GRANT (B) | 2019-2025 | $14,811,581 |
| HHS | UH3HL147011 | COOPERATIVE AGREEMENT (B) | 2020-2026 | $9,788,465 |
| HHS | C06OD039902 | PROJECT GRANT (B) | 2025-2028 | $7,947,160 |
| HHS | U54CA274374 | COOPERATIVE AGREEMENT (B) | 2022-2027 | $7,696,898 |
| HHS | R33HL151885 | PROJECT GRANT (B) | 2020-2026 | $7,589,270 |
| HHS | U01CA173642 | COOPERATIVE AGREEMENT (B) | 2013-2025 | $7,510,704 |
| HHS | R01AI054423 | PROJECT GRANT (B) | 2003-2027 | $7,433,157 |
| HHS | R01CA114536 | PROJECT GRANT (B) | 2005-2026 | $7,167,964 |
| HHS | R01AR045203 | PROJECT GRANT (B) | 1998-2026 | $7,131,390 |
| HHS | R35CA231989 | PROJECT GRANT (B) | 2018-2026 | $6,262,008 |
| HHS | U54CA243125 | COOPERATIVE AGREEMENT (B) | 2019-2025 | $6,164,669 |
| HHS | R35CA253119 | PROJECT GRANT (B) | 2021-2028 | $5,450,329 |
| HHS | U01CA182883 | COOPERATIVE AGREEMENT (B) | 2013-2025 | $5,409,067 |
| HHS | R01GM074108 | PROJECT GRANT (B) | 2005-2025 | $5,095,366 |
| HHS | P50CA285275 | PROJECT GRANT (B) | 2024-2029 | $5,031,369 |
| HHS | U19MD020533 | COOPERATIVE AGREEMENT (B) | 2024-2029 | $5,025,129 |
| USDA | 20226701738475 | PROJECT GRANT (B) | 2022-2026 | $4,969,948 |
+ 80 more awards
Source: USAspending.gov. Amounts represent total federal obligations.
Get in touch with Fred Hutchinson Cancer Center